# A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

> **NCT04489771** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 154 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Belzutifan

## Key facts

- **NCT ID:** NCT04489771
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-13
- **Primary completion:** 2023-02-10
- **Final completion:** 2026-10-04
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04489771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04489771, "A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04489771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*